Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.52 |
| ▸ | MTNR1A | P48039 | 5/20 | 0.48 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.48 |
| ▸ | METAP1 | P53582 | 1/20 | 0.45 |
| ▸ | NQO2 | P16083 | 3/20 | 0.44 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.43 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31366772 | 1.00 | ACHE (0.52) | ACHECYP19A1MTNR1AMTNR1BMETAP1 | |
| SCHEMBL7979383 | 0.89 | CYP19A1 (0.55) | ACHECYP19A1MTNR1AMTNR1BMETAP1 | |
| SCHEMBL345475 | 0.87 | ACHE (0.51) | ACHECYP19A1MTNR1AMTNR1BMETAP1 | |
| SCHEMBL14469511 | 0.86 | MAPK1 (0.53) | ACHECYP19A1MTNR1AMTNR1BMETAP1 | |
| SCHEMBL13254661 | 0.86 | MAPK1 (0.53) | ACHECYP19A1MTNR1AMTNR1BMETAP1 | |
| SCHEMBL7771760 | 0.85 | ACHE (0.63) | ACHEMTNR1AMTNR1BMETAP1KDM4E | |
| SCHEMBL31366725 | 0.84 | CYP19A1 (0.51) | ACHECYP19A1CYP26A1CYP24A1KDM4E | |
| SCHEMBL10333984 | 0.84 | CYP19A1 (0.48) | ACHECYP19A1MTNR1AMTNR1BMETAP1 | |
| SCHEMBL8435265 | 0.83 | ALDH1A1 (0.56) | ACHECYP19A1MTNR1AMTNR1BMETAP1 | |
| SCHEMBL31650300 | 0.81 | CYP19A1 (0.48) | ACHECYP19A1MTNR1AMTNR1BMETAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150011759-A1 | PROCESSES FOR PREPARING (R)-2-METHYLPYRROLIDINE AND (S)-2-METHYLPYRROLIDINE AND TARTRATE SALTS THEREOF | CEPHALON, INC. (US) | 2015-01-08 | — | — | US | disclosed |
| US-20150011759-A1 | PROCESSES FOR PREPARING (R)-2-METHYLPYRROLIDINE AND (S)-2-METHYLPYRROLIDINE AND TARTRATE SALTS THEREOF | CEPHALON, INC. (US) | 2015-01-08 | — | — | US | disclosed |
| EP-1988777-B1 | PYRAZOLES FOR THE TREATMENT OF OBESITY AND OTHER CNS DISORDERS | ATHERSYS INC (US) | 2011-09-21 | — | — | EP | disclosed |
| EP-1988777-B1 | PYRAZOLES FOR THE TREATMENT OF OBESITY AND OTHER CNS DISORDERS | ATHERSYS INC (US) | 2011-09-21 | — | — | EP | disclosed |
| US-7981896-B2 | Pyrazoles for the treatment of obesity and other CNS disorders | ATHERSYS, INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-7981896-B2 | Pyrazoles for the treatment of obesity and other CNS disorders | ATHERSYS, INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-7981896-B2 | Pyrazoles for the treatment of obesity and other CNS disorders | ATHERSYS, INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-20110112088-A1 | PYRAZOLES FOR THE TREATMENT OF OBESITY AND OTHER CNS DISORDERS | BENNANI YOUSSEF L | 2011-05-12 | — | — | US | disclosed |
| US-20110112088-A1 | PYRAZOLES FOR THE TREATMENT OF OBESITY AND OTHER CNS DISORDERS | BENNANI YOUSSEF L | 2011-05-12 | — | — | US | disclosed |
| US-20110112088-A1 | PYRAZOLES FOR THE TREATMENT OF OBESITY AND OTHER CNS DISORDERS | BENNANI YOUSSEF L | 2011-05-12 | — | — | US | disclosed |
| US-7897634-B2 | Pyrazoles for the treatment of obesity and other CNS disorders | ATHERSYS, INC. (US) | 2011-03-01 | — | — | US | disclosed |
| US-7897634-B2 | Pyrazoles for the treatment of obesity and other CNS disorders | ATHERSYS, INC. (US) | 2011-03-01 | — | — | US | disclosed |
| US-7897634-B2 | Pyrazoles for the treatment of obesity and other CNS disorders | ATHERSYS, INC. (US) | 2011-03-01 | — | — | US | disclosed |
| US-20100121055-A1 | PROCESSES FOR PREPARING (R)-2-METHYLPYRROLIDINE AND (S)-2-METHYLPYRROLIDINE AND TARTRATE SALTS THEREOF | CEPHALON, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100121055-A1 | PROCESSES FOR PREPARING (R)-2-METHYLPYRROLIDINE AND (S)-2-METHYLPYRROLIDINE AND TARTRATE SALTS THEREOF | CEPHALON, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| WO-2008137087-A1 | PROCESSES FOR PREPARING (R)-2-METHYLPYRROLIDINE AND (S)-2-METHYLPYRROLIDINE AND TARTRATE SALTS THEREOF | CEPHALON, INC. (US) | 2008-11-13 | — | — | WO | disclosed |
| US-20070197526-A1 | Pyrazoles for the treatment of obesity and other CNS disorders | ATHERSYS, INC. | 2007-08-23 | — | — | US | disclosed |
| US-20070197526-A1 | Pyrazoles for the treatment of obesity and other CNS disorders | ATHERSYS, INC. | 2007-08-23 | — | — | US | disclosed |
| US-20070197526-A1 | Pyrazoles for the treatment of obesity and other CNS disorders | ATHERSYS, INC. | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011759-A1 | PROCESSES FOR PREPARING (R)-2-METHYLPYRROLIDINE AND (S)-2-METHYLPYRROLIDINE AND TARTRATE SALTS THEREOF | TPMT, SPR, QDPR | ACHE 58/4885CYP19A1 3902/4885MTNR1A 2460/4885 |
| US-20100121055-A1 | PROCESSES FOR PREPARING (R)-2-METHYLPYRROLIDINE AND (S)-2-METHYLPYRROLIDINE AND TARTRATE SALTS THEREOF | TPMT, SPR, QDPR | ACHE 58/4885CYP19A1 3902/4885MTNR1A 2460/4885 |
| US-20110112088-A1 | PYRAZOLES FOR THE TREATMENT OF OBESITY AND OTHER CNS DISORDERS | GPR119, HCRTR2, HCRTR1 | ACHE 376/4885CYP19A1 162/4885MTNR1A 358/4885 |
| US-20070197526-A1 | Pyrazoles for the treatment of obesity and other CNS disorders | HRH3, HRH4, HRH2 | ACHE 373/4885CYP19A1 1667/4885MTNR1A 255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.